APEN:NSD-Apollo Endosurgery Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 9.32

Change

+0.12 (+1.30)%

Market Cap

USD 0.26B

Volume

0.22M

Avg Analyst Target

USD 12.50 (+34.12%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

-1.87 (-0.26%)

USD56.71B 124.35 55.99
PODD Insulet Corporation

-1.40 (-0.48%)

USD20.01B 2,208.27 244.52
ABMD Abiomed Inc

-0.25 (-0.07%)

USD15.91B 103.67 53.06
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-0.29 (-0.34%)

USD12.64B 81.79 28.22
SWAV ShockWave Medical Inc

-5.12 (-2.25%)

USD8.00B N/A N/A
TNDM Tandem Diabetes Care Inc

-1.72 (-1.37%)

USD7.91B 1,218.35 239.94
INMD InMode Ltd

+5.43 (+3.17%)

USD6.53B 57.19 40.15
IART Integra LifeSciences Holdings ..

-0.15 (-0.21%)

USD6.12B 29.96 19.16
LIVN LivaNova PLC

-0.47 (-0.57%)

USD4.37B 77.40 N/A

ETFs Containing APEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 174.12% 93% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 174.12% 93% A 97% A+
Trailing 12 Months  
Capital Gain 560.99% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 560.99% 100% A+ 98% A+
Trailing 5 Years  
Capital Gain -99.74% 11% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.74% 11% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 24.73% 49% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.73% 49% F 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 136.24% 18% F 11% F
Risk Adjusted Return 18.15% 30% F 32% F
Market Capitalization 0.26B 41% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 93.91 1% F 1% F
Price / Cash Flow Ratio -12.69 54% F 75% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -509.60% 4% F 11% F
Return on Invested Capital -26.76% 49% F 25% F
Return on Assets -12.84% 45% F 25% F
Debt to Equity Ratio 838.08% 5% F 2% F
Technical Ratios  
Short Ratio 2.39 64% D 60% D-
Short Percent 1.84% 80% B- 62% D-
Beta 2.31 10% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector